+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents



Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents



Current Drug Targets 13(11): 1432-1444



Redox homeostasis is crucial for the cellular viability and normal function which balance is maintained by two major cellular antioxidant systems, including glutathione system and thioredoxin system. Thioredoxin system, including thioredoxin (Trx), thioredoxin reductase (TrxR) and NADPH, exhibits a wide range of functions such as regulation of redox state and cell apoptosis. Particularly, Trx functions as a protein disulfide reductase which is essential for the function of Trx system. However, the bioactivity of Trx is closely dependent on its reducing form. According to the information, TrxR is the only cellular enzyme to catalyze the NADPH-dependent reduction of Trx. Besides the reduction of some protein disulfide like Trx, TrxR still has a broad substrate specificity to reduce some small molecules like 5, 5 '-dithiobis-2- nitrobenzoic acid (DTNB). The reduction of Trx or its own direct action towards its various substrates endows TrxR with a wide range of cellular functions. Recent studies have elucidated that TrxR was upregulated in many malignant tumors and inhibition of TrxR could prevent the tumor initiation and progression, suggesting TrxR to be a promising target for cancer therapy and the high nucleophilic and accessible selenocysteine (Sec) active site might be the prime target for drug design. Various kinds of TrxR inhibitors have been developed as anticancer agents for years. In this review, TrxR inhibitors are divided into three classes, including metal-containing inhibitors, naturally occurring products and their derivatives and other newly emerged inhibitors. The last five years reports about TrxR inhibitors of each class will be introduced and their novel inhibiting mechanisms will be discussed.

(PDF emailed within 1 workday: $29.90)

Accession: 055398890

Download citation: RISBibTeXText

PMID: 22876886


Related references

Metal- and Semimetal-Containing Inhibitors of Thioredoxin Reductase as Anticancer Agents. Molecules 20(7): 12732-12756, 2016

Recent advances in the development of catalytic inhibitors of human DNA topoisomerase II╬▒ as novel anticancer agents. Current Medicinal Chemistry 20(5): 694-709, 2014

Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family. Leukemia 17(8): 1470-1481, 2003

Small molecule inhibitors of mammalian thioredoxin reductase as potential anticancer agents: An update. Medicinal Research Reviews 39(1): 5-39, 2018

Recent Advances in the Design and Synthesis of c-Met Inhibitors as Anticancer Agents (2014-Present). Current Medicinal Chemistry 24(1): 57-64, 2016

Recent Advances in Development of Polyphenols as Anticancer Agents. Mini Reviews in Medicinal Chemistry 18(15): 1265-1269, 2018

Design, Synthesis, and Biological Evaluation of Coupled Bioactive Scaffolds as Potential Anticancer Agents for Dual Targeting of Dihydrofolate Reductase and Thioredoxin Reductase. Journal of Medicinal Chemistry 60(5): 1734-1745, 2017

Recent advances in aldose reductase inhibitors: potential agents for the treatment of diabetic complications. Expert Opinion on Therapeutic Patents 12(5): 621-631, 2002

Recent Advances in the Development of Indazole-based Anticancer Agents. Chemmedchem 13(15): 1490-1507, 2018

Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs. Current Medicinal Chemistry 17(35): 4270-4290, 2011

Targeting thioredoxin reductase: anticancer agents and chemopreventive compounds. Medicinal Chemistry ) 6(5): 286-297, 2011

Targeting Thioredoxin Reductase: Anticancer Agents and Chemopreventive Compounds. Medicinal Chemistry 6(5): 286-297, 2010

Mechanism inspired development of rationally designed dihydrofolate reductase inhibitors as anticancer agents. Journal of Medicinal Chemistry 55(14): 6381-6390, 2012

The Recent Development of Farnesyltransferase Inhibitors as Anticancer and Antimalarial Agents. Mini Reviews in Medicinal Chemistry 15(10): 837-857, 2016

Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs. European Journal of Medicinal Chemistry 108: 495-504, 2016